Business Description
Madrigal Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US5588681057
Description
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 8.96 | |||||
| Equity-to-Asset | 0.78 | |||||
| Debt-to-Equity | 0.14 | |||||
| Debt-to-EBITDA | -0.24 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 9.09 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -13 | |||||
| 3-Year EPS without NRI Growth Rate | -15.2 | |||||
| 3-Year FCF Growth Rate | -19.5 | |||||
| 3-Year Book Growth Rate | 9.6 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 63.04 | |||||
| 9-Day RSI | 55.48 | |||||
| 14-Day RSI | 49.82 | |||||
| 6-1 Month Momentum % | 4.02 | |||||
| 12-1 Month Momentum % | 68.23 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 8.72 | |||||
| Quick Ratio | 8.67 | |||||
| Cash Ratio | 8.45 | |||||
| Days Inventory | 2274.36 | |||||
| Days Sales Outstanding | 172.03 | |||||
| Days Payable | 10633.09 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -8.6 | |||||
| Shareholder Yield % | -14.55 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 95.66 | |||||
| Operating Margin % | -3622.65 | |||||
| Net Margin % | -3487.13 | |||||
| FCF Margin % | -3113.94 | |||||
| ROE % | -113.99 | |||||
| ROA % | -75.89 | |||||
| ROIC % | -2753.15 | |||||
| 3-Year ROIIC % | -1242.75 | |||||
| ROC (Joel Greenblatt) % | -18902.68 | |||||
| ROCE % | -88.3 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 330.52 | |||||
| PB Ratio | 6.57 | |||||
| Price-to-Tangible-Book | 6.6 | |||||
| EV-to-EBIT | -7.57 | |||||
| EV-to-Forward-EBIT | -7.02 | |||||
| EV-to-EBITDA | -7.58 | |||||
| EV-to-Forward-EBITDA | -7.05 | |||||
| EV-to-Revenue | 256.09 | |||||
| EV-to-Forward-Revenue | 9.61 | |||||
| EV-to-FCF | -8.22 | |||||
| Price-to-Net-Current-Asset-Value | 6.63 | |||||
| Price-to-Net-Cash | 6.9 | |||||
| Earnings Yield (Greenblatt) % | -13.21 | |||||
| FCF Yield % | -8.09 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MDGL
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Madrigal Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 14.638 | ||
| EPS (TTM) ($) | -25.54 | ||
| Beta | -1.33 | ||
| Volatility % | 72.47 | ||
| 14-Day RSI | 49.82 | ||
| 14-Day ATR ($) | 6.870032 | ||
| 20-Day SMA ($) | 211.6825 | ||
| 12-1 Month Momentum % | 68.23 | ||
| 52-Week Range ($) | 130.78 - 299.98 | ||
| Shares Outstanding (Mil) | 21.71 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Madrigal Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Madrigal Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Madrigal Pharmaceuticals Inc Frequently Asked Questions
What is Madrigal Pharmaceuticals Inc(MDGL)'s stock price today?
The current price of MDGL is $259.34. The 52 week high of MDGL is $299.98 and 52 week low is $130.78.
When is next earnings date of Madrigal Pharmaceuticals Inc(MDGL)?
The next earnings date of Madrigal Pharmaceuticals Inc(MDGL) is 2024-10-31.
Does Madrigal Pharmaceuticals Inc(MDGL) pay dividends? If so, how much?
Madrigal Pharmaceuticals Inc(MDGL) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers